Consumer Goods - Germany



**Buy** (old: Buy) 15.02.2024

**EUR 8.00** (old: EUR 8.60)

### Strategic transactions closed; est. & PT chg.

Marley Spoon Group ("MSG") closed the strategic transactions announced on January 31st. Here is what you need to know:

Acquisition of BistroMD. MSG closed the acquisition of BistroMD, a leading doctor-designed ready-to-eat (RTE) meal plan company in the US (c.  $\in$  35m revenues in 2023), offering MSG an opportunity to use its own data and technology platform to generate synergies and performance improvements over time. While BistroMD should currently be loss-making due to lack of sufficient scale (c. 30% contribution margin, eNuW), fulfilment, G&A, and marketing expenses are seen to decrease significantly from currently c.  $\in$  27.5m (eNuW) to c.  $\in$  20m by 2025e (eNuW) thanks to the integration into MSG's platform. In sum, we regard BistroMD as a strategically sensible add-on as it adds a double-digit growing RTE business that capitalizes on the increasing health & wellness consciousness of the American consumer.


Depending on the underlying share price assumed, the acquisition price of around  $\in$  15m (eNuW) comprises c.  $\in$  11-13m in debt as well as 1.4m MSG shares, along with an earn-out of up to 1.2m additional shares (12 months post-closing), and 450k warrants with strike prices ranging from  $\in$  15 to  $\in$  20. Assuming a share price of  $\in$  2.00, MSG acquires BistroMD at an EV/Sales FY23 multiple 0.43x, a 48% premium to MSG's own current valuation of 0.29x.

Partnership with FreshRealm. Furthermore, MSG entered into a 7-year strategic partnership for manufacturing and fulfilment with FreshRealm by selling its US operating assets for € 22m to FreshRealm, which will operate the fulfilment centre and become MSG's exclusive operations partner in the US. This provides Marley Spoon with a scalable and capital-efficient way of operating in the US, delegating assetheavy fulfilment and warehouse operations (back-end) to an experienced partner while continuing to focus its investments on customer-facing competencies (front-end). Net cost savings are seen to amount to c. € 1-2m in G&A and should thus favourably impact margins going forward.

- continued -

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	254.0	322.4	401.2	328.5	384.1	426.5
Sales growth	96.1%	26.9%	24.5%	-18.1%	16.9%	11.0%
EBITDA	-0.9	-34.3	-11.5	-14.9	0.9	9.1
Net debt (if net cash=0)	-13.3	17.9	59.6	56.4	59.7	67.5
FCF	-4.2	-36.5	-29.4	-22.2	-14.9	1.1
Net Debt/EBITDA	0.0	-0.5	-5.2	-3.8	64.5	7.4
EPS pro forma	-460.78	-173.62	-1.33	-2.68	-1.10	-0.59
EBITDA margin	-0.4%	-10.6%	-2.9%	-4.5%	0.2%	2.1%
ROCE	-33.1%	-119.4%	-71.2%	-104.7%	-93.3%	-30.3%
EV/sales	-0.0	0.1	0.4	0.3	0.3	0.3
EV/EBITDA	11.6	-0.8	-12.3	-6.4	116.9	12.7
PER	-0.0	-0.2	-2.1	-1.0	-2.5	-4.7
Adjusted FCF yield	-45.7%	-59.0%	-2.0%	1.7%	14.3%	18.1%

Source: Company data, NuWays, Close price as of 14.02.2024



iviai ket uata	
Share price (in €)	2.62
Market cap (in € m)	48.5
Number of shares (in m pcs)	17.6
Enterprise value (in € m)	108.2
Ø trading volume (6 months)	1,080

Market data

Identifier						
Bloomberg Reuters	MS1 GR MS1 DF					
WKN	A3C81B					
ISIN	LU2380748603					


Key shareholders				
468 Capital	17.4%			
Union Square Ventures	12.1%			
Sudeep Ramesh Ramnani	11.9%			
Conifer Management	5.7%			
BistroMD	7.0%			
Free Float	15.1%			


Estimates changes							
	<u>2023e</u>	<u>2024e</u>	<u>2025e</u>				
Sales	0%	11%	11%				
EBIT	0%	-193%	-814%				
EPS	0%	-26%	11%				

### Comment on changes

- Revenue contribution from BistroMD
- Cost synergies (G&A, fulfilment) from FreshRealm and BistroMD
- Inclusion of capital increase

480.0m						_
360.0m						
240.0m						
120.0m						
0.0m						
	2020	2021	2022	2023e	2024e	2025e
Source: Nu	Ways Re	search				





### Company description

Sales (2020-25e)

Marley Spoon is a global direct-to-consumer meal kit delivery company. The company offers customers meal kits through its two brands Marley Spoon and Dinnerly and ready-to-heat meals through its brand Chefgood. Marley Spoon serves customers in the US, Australia, and Europe.

### Guidance

Update - 15.02.2024



**Debt terms & capital raise**. Both deals are supported by an c. € 8m equity raise through c. 2m treasury shares at € 4.00 per share. Moreover, Runway, the company's biggest debtholder, supports these transactions and agreed to a 12-months extension of the debt facilities' interest-only period to January 2026 and maturity date to June 2027. Upon closure of the transactions, MSG will repay Runway € 10.3m of the outstanding loan balance. Importantly, the asset sale, capital raise, and debt facility extension provide Marley Spoon with ample breathing room to reinvigorate its meal-kit and adjacent operations as well as time to successfully integrate its recent acquisitions.

**Growth outlook**. Including the financial impact of the transactions described above, Marley Spoon is well-positioned to return to profitable topline growth, reaching c. € 384m sales (+16.9% yoy, eNuW) and c. € 2m operating EBITDA (+1.4ppts yoy, eNuW) in FY24e. This should mainly be driven by a return to active customer growth to c. 211k (+ 12% yoy, eNuW), and leverage in its multi-region and multi-brand meal kit platform to

- further penetrate the still vastly underpenetrated \$ 7tn global food & grocery market, harnessing deep-seated consumer trends like convenience and wellness;
- grow basket size via more differentiated service offerings (Al-driven recipe development and ranking for +100 weekly recipe options);
- and realize revenue and cost synergies from its newly acquired BistroMD and FreshRealm partnerships going forward.

The Group **remains attractively priced** trading at only 0.28x EV/Sales 2024e, leading us to reiterate our **BUY rating with a changed PT of € 8.00** (old: € 8.60) based on DCF.

### Brand & product offering overview of MSG



Source: Company data, NuWays

Update - 15.02.2024



## **Financials**

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	254.0	322.4	401.2	328.5	384.1	426.5
Sales growth	96.1%	26.9%	24.5%	-18.1%	16.9%	11.0%
Cost of sales	133.3	173.3	216.8	173.8	201.4	221.7
Gross profit	120.7	149.1	184.4	154.7	182.7	204.9
Sales and marketing	39.3	71.2	64.0	55.6	66.3	72.4
General and administration	42.3	64.0	79.0	80.3	73.1	73.3
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	0.0	0.0	0.0	0.0	0.0	0.0
Other operating expenses	46.6	57.3	69.1	50.6	58.0	62.0
Total operating expenses	128.2	192.5	212.1	186.5	197.4	207.7
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-0.9	-34.3	-11.5	-14.9	0.9	9.1
Depreciation	4.7	7.2	10.6	11.8	9.9	5.9
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.8	2.0	5.5	5.1	5.7	6.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	-7.4	-43.4	-27.6	-31.8	-14.7	-2.8
Interest income	0.1	2.8	0.1	0.0	0.0	0.0
Interest expenses	7.4	6.0	12.3	12.8	8.0	9.3
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-7.4	-3.2	-12.2	-12.8	-8.0	-9.3
Recurring pretax income from continuing operations	-14.8	-46.6	-39.9	-44.6	-22.7	-12.2
Extraordinary income/loss	-71.4	0.1	-0.0	0.0	0.0	0.0
Earnings before taxes	-86.2	-46.4	-39.9	-44.6	-22.7	-12.2
Income tax expense	0.1	0.1	0.1	0.0	0.0	0.0
Net income from continuing operations	-86.4	-46.6	-40.0	-44.6	-22.7	-12.2
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-86.4	-46.6	-40.0	-44.6	-22.7	-12.2
Minority interest	-0.1	-0.4	-0.3	-6.7	-3.4	-1.8
Net profit (reported)	-86.2	-46.2	-39.7	-37.9	-19.3	-10.4
Average number of shares	0.2	0.3	30.0	14.1	17.6	17.6
		.=				
EPS reported	-460.78	-173.62	-1.33	-2.68	-1.10	-0.59
						-0.59
Profit and loss (common size)	2020	2021	2022	2023e	2024e	-0.59 2025e
EPS reported  Profit and loss (common size)  Sales Cost of sales	2020 100.0%	2021 100.0%	2022 100.0%	2023e 100.0%	2024e 100.0%	-0.59 2025e 100.0%
Profit and loss (common size)  Sales  Cost of sales	2020 100.0% 52.5%	2021 100.0% 53.8%	2022 100.0% 54.0%	2023e 100.0% 52.9%	2024e 100.0% 52.4%	-0.59 2025e 100.0% 52.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit	2020 100.0% 52.5% 47.5%	2021 100.0% 53.8% 46.2%	2022 100.0% 54.0% 46.0%	2023e 100.0% 52.9% 47.1%	2024e 100.0% 52.4% 47.6%	-0.59 2025e 100.0% 52.0% 48.0%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing	2020 100.0% 52.5% 47.5% 15.5%	2021 100.0% 53.8% 46.2% 22.1%	2022 100.0% 54.0% 46.0% 16.0%	2023e 100.0% 52.9% 47.1% 16.9%	2024e 100.0% 52.4% 47.6% 17.3%	-0.59 2025e 100.0% 52.0% 48.0% 17.0%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration	2020 100.0% 52.5% 47.5% 15.5% 16.6%	2021 100.0% 53.8% 46.2% 22.1% 19.8%	2022 100.0% 54.0% 46.0% 16.0% 19.7%	2023e 100.0% 52.9% 47.1% 16.9% 24.4%	2024e 100.0% 52.4% 47.6% 17.3% 19.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0%	2021 100.0% 53.8% 46.2% 22.1%	2022 100.0% 54.0% 46.0% 16.0%	2023e 100.0% 52.9% 47.1% 16.9%	2024e 100.0% 52.4% 47.6% 17.3%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 0.0%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0% 15.4%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0% 15.1%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 0.0% 14.5%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 0.0% 14.5% 48.7%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0% 15.4% 56.8%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0% 15.1% 51.4%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 0.0% 14.5% 48.7% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0% 15.4% 56.8% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0% 51.1% 51.4% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 0.0% 14.5% 48.7%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 0.0% 51.4% 0.0% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 14.5% 48.7% 0.0% 2.1%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 55.1% 51.4% 0.0% 0.2% 2.6%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 14.5% 48.7% 0.0% 2.1% 1.4% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 14.5% 48.7% 0.0% 2.1%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 0.0% 14.5% 48.7% 0.0% 2.1% 1.4% 0.0% 1.4%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 0.0% 14.5% 48.7% 0.0% 2.1% 1.4% 0.0% 1.4% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% -9.7%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 14.5% 48.7% 0.0% 2.1% 1.4% 0.0% 1.4% 0.0% -0.7%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% -9.7% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0%	-0.59 2025e 100.0% 52.0% 48.0% 17.0% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% 1.4% 0.0% -0.7% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 3.9%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 3.9% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 0.0% 14.5% 0.0% 2.1% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg.	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg.	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg.	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 3.9% 0.0% neg.	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg.	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg.
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg5.8%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg14.5%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg9.9%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg5.9%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg2.9%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg5.8% -28.1%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg14.5% 0.0%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg9.9% -0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg5.9% 0.0%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg2.9% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg5.8% -28.1% -33.9%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg14.5% 0.0% -14.4%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg9.9% -0.0% -9.9%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% 0.0% 1.5% 0.0% 1.5% 0.0% -9.7% 0.0% a.9% 0.0% neg13.6% 0.0% -13.6%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 0.2% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg5.9%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 0.0% 0.0% 14.5% 48.7% 0.0% 2.1% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg2.9% 0.0% -2.9%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg5.8% -28.1% -33.9% -0.2%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg14.5% 0.0% -14.4% -0.3%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg9.9% -0.0% -9.9% -0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% -9.7% 0.0% 3.9% 0.0% neg13.6% 0.0% -13.6% 0.0%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg5.9% 0.0%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg2.9% 0.0% -2.9% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  Unusual or infrequent items  EBITDA  Depreciation  Amortisation of goodwill  Amortisation of intangible assets Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate  Net income from continuing operations	2020 100.0% 52.5% 47.5% 15.5% 16.6% 0.0% 0.0% 18.3% 50.5% 0.0% -0.4% 1.9% 0.0% 0.7% 0.0% -2.9% 0.0% 2.9% 0.0% neg5.8% -28.1% -33.9% -0.2% -34.0%	2021 100.0% 53.8% 46.2% 22.1% 19.8% 0.0% 0.0% 17.8% 59.7% 0.0% -10.6% 2.2% 0.0% 0.6% 0.0% -13.5% 0.9% 1.9% 0.0% neg14.5% 0.0% -14.4% -0.3% -14.4%	2022 100.0% 54.0% 46.0% 16.0% 19.7% 0.0% 0.0% 17.2% 52.8% 0.0% -2.9% 2.6% 0.0% 1.4% 0.0% -6.9% 0.0% 3.1% 0.0% neg9.9% -0.0% -9.9% -0.0% -9.9% -0.0%	2023e 100.0% 52.9% 47.1% 16.9% 24.4% 0.0% 15.4% 56.8% 0.0% -4.5% 3.6% 0.0% 1.5% 0.0% -9.7% 0.0% 3.9% 0.0% neg13.6% 0.0% -13.6% 0.0% -13.6%	2024e 100.0% 52.4% 47.6% 17.3% 19.0% 0.0% 15.1% 51.4% 0.0% 2.6% 0.0% 1.5% 0.0% -3.8% 0.0% 2.1% 0.0% neg5.9% 0.0% -5.9%	-0.59  2025e 100.0% 52.0% 48.0% 17.0% 17.2% 0.0% 14.5% 48.7% 0.0% 1.4% 0.0% -0.7% 0.0% 2.2% 0.0% neg2.9% 0.0% -2.9%

Source: Company data, NuWays

Update - 15.02.2024



Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	4.9	8.8	25.4	28.6	30.2	33.5
Property, plant and equipment	21.0	48.7	47.4	39.5	23.6	21.2
Financial assets	3.0	2.9	2.9	2.9	2.9	2.9
FIXED ASSETS	29.0	60.4	75.7	71.1	56.8	57.6
Inventories	6.6	9.4	13.1	11.6	14.4	15.8
Accounts receivable	0.7	0.4	0.8	0.7	0.8	0.9
Other assets and short-term financial assets	2.4	3.7	3.2	3.2	3.2	3.2
Liquid assets	34.4	38.7	19.0	10.5	6.4	9.6
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	44.1	52.2	36.2	26.0	24.8	29.5
TOTAL ASSETS	73.1	112.6	111.9	97.1	81.6	87.1
SHAREHOLDERS EQUITY	9.1	-16.3	-41.5	-39.3	-50.9	-58.7
MINORITY INTEREST	-0.9	-1.3	- <b>41.5</b> -1.6	- <b>39.3</b> -6.9	-9.0	- <b>36.7</b> -10.4
	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations Other provisions and accrued liabilities	3.5	1.0	2.3	2.3	2.3	2.3
Short-term liabilities to banks	3.4	7.3	2.3 7.8	2.3 7.8	2.3 7.8	2.3 7.8
	3. <del>4</del> 17.5	7.3 27.6	7.6 26.4	26.4	7.6 25.4	7.6 29.2
Accounts payable Advance payments received on orders	0.9	3.6	1.9	1.9	1.9	1.9
Other liabilities (incl. from lease and rental contracts)	21.9	41.5	44.0	44.0	44.0	44.0
Deferred taxes	0.0	0.0	1.8	1.8	1.8	1.8
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	40.3	72.6	72.3	72.3	71.3	75.1
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	73.1	112.6	111.9	97.1	81.6	87.1
· ·						
Balance sheet (common size)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	6.8%	7.8%	22.7%	29.5%	37.0%	38.4%
Property, plant and equipment	28.8%	43.2%	42.3%	40.7%	29.0%	24.4%
Financial assets	4.2%	2.6%	2.6%	3.0%	3.6%	3.4%
FIXED ASSETS	39.7%	53.6%	67.7%	73.2%	69.6%	66.1%
Inventories	9.0%	8.3%	11.7%	12.0%	17.6%	18.2%
Accounts receivable	1.0%	0.4%	0.7%	0.7%	1.0%	1.0%
Other assets and short-term financial assets	3.2%	3.3%	2.9%	3.3%	4.0%	3.7%
Liquid assets	47.1%	34.3%	17.0%	10.8%	7.8%	11.0%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT ASSETS	60.3%	46.4%	32.3%	26.8%	30.4%	33.9%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	12.4%	-14.5%	-37.1%	-40.4%	-62.4%	-67.4%
MINORITY INTEREST	-1.3%	-1.1%	-1.4%	-7.1%	-11.0%	-11.9%
Provisions for pensions and similar obligations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other provisions and accrued liabilities	4.8%	0.9%	2.0%	2.3%	2.8%	2.6%
Short-term liabilities to banks	4.7%	6.5%	7.0%	8.1%	9.6%	9.0%
Accounts payable	23.9%	24.5%	23.6%	27.2%	31.1%	33.5%
Advance payments received on orders	1.3%	3.2%	1.7%	1.9%	2.3%	2.2%
• •	00.00/	36.8%	39.4%	45.4%	54.0%	50.5%
Other liabilities (incl. from lease and rental contracts)	30.0%	00.070				
Other liabilities (incl. from lease and rental contracts) Deferred taxes	0.0%	0.0%	1.6%	1.8%	2.2%	2.0%
,						
Deferred taxes	0.0%	0.0%	1.6%	1.8%	2.2%	2.0% 0.0% <b>86.1%</b> <b>100.0%</b>

Source: Company data, NuWays

Update - 15.02.2024



Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025e
Net profit/loss	-86.4	-46.6	-40.0	-44.6	-22.7	-12.2
Depreciation of fixed assets (incl. leases)	4.7	7.2	10.6	11.8	9.9	5.9
Amortisation of goodwill & intangible assets	1.8	2.0	5.5	5.1	5.7	6.0
Others	-6.0	-9.3	-17.0	-8.9	-8.9	-8.9
Cash flow from operating activities	4.4	-14.9	-18.7	-9.9	-1.1	13.4
Increase/decrease in inventory Increase/decrease in accounts receivable	-2.8 -0.2	-2.8 -0.9	-3.7 -1.0	1.5 0.1	-2.8 -0.1	-1.4 -0.1
	-0.2 7.5	-0.9 13.5	-1.0 -1.4	0.1	-0.1 -1.0	3.8
Increase/decrease in accounts payable Increase/decrease in other working capital positions	0.4	6.5	-1. <del>4</del> -0.6	0.0	0.0	0.0
Increase/decrease in working capital	4.9	16.3	-0.6 -6.6	1.6	-3.9	2.2
Cash flow from operating activities	4.9	-14.9	-18.7	-9.9	-3.9 -1.1	13.4
CAPEX	-8.6	-21.5	-10.7	-12.3	-13.8	-12.3
Payments for acquisitions	0.0	0.0	-7.8	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	22.0	0.0
Cash flow from investing activities	-8.6	-21.5	-18.5	-12.3	8.2	-12.3
Cash flow before financing	-4.2	-36.5	-29.4	-22.2	-14.9	1.1
Increase/decrease in debt position	-4.1	50.9	18.8	-11.7	-10.3	11.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	43.8	0.0	15.9	34.7	8.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-6.0	-9.3	-17.0	-8.9	-8.9	-8.9
Effects of exchange rate changes on cash	-0.5	-0.9	0.0	-0.5	0.0	0.0
Cash flow from financing activities	33.7	41.6	17.6	14.1	-11.2	2.1
Increase/decrease in liquid assets	29.0	4.2	-11.8	-8.5	-26.1	3.2
Liquid assets at end of period	34.5	38.7	19.0	10.5	6.4	9.6
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025e
P&L growth analysis						
Sales growth	96.1%	26.9%	24.5%	-18.1%	16.9%	11.0%
EBITDA growth	-96.9%	3559.8%	-66.3%	28.9%	-106.2%	883.6%
EBIT growth	-78.6%	484.5%	-36.3%	15.0%	-53.8%	-80.6%
EPS growth	94.8%	-62.3%	-99.2%	102.1%	-59.1%	-46.3%
Efficiency						
Sales per employee	274.2	234.1	239.4	166.7	182.0	268.9
EBITDA per employee	-1.0	-24.9	-6.9	-7.6	0.4	5.7
No. employees (average)	926	1,377	1,676	1,970	2,110	1,586
Balance sheet analysis	2.22/		. =0/		0 =0/	0.40/
Avg. working capital / sales	-3.9%	-5.0%	-4.5%	-4.6%	-3.7%	-3.1%
Inventory turnover (sales/inventory)	20.3	18.5	16.5	14.0	14.0	14.0
Accounts receivable turnover	1.0	0.5	0.7	0.7	0.7	0.7
Accounts payable turnover	47.8	58.1	44.4	44.0	46.0	48.0
Cash flow analysis Free cash flow	-4.2	-36.5	-29.4	-22.2	-14.9	1.1
Free cash flow/sales	-4.2 -1.6%	-11.3%	-29.4 -7.3%	-22.2 -6.7%	-3.9%	0.3%
FCF / net profit	4.8%	78.3%	73.6%	49.7%	-5.9 % 65.8%	neg.
Capex / sales	-3.4%	-6.7%	-2.7%	-3.7%	-3.6%	-2.9%
Solvency	-3.470	-0.1 /0	-2.1 /0	-3.7 /0	-3.070	-2.570
Net debt	-13.3	17.9	59.6	56.4	59.7	67.5
Net Debt/EBITDA	0.0	-0.5	-5.2	-3.8	64.5	7.4
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	22.4%	15.4%	18.2%	17.6%	12.1%	13.1%
Returns						
				104 70/	-93.3%	-30.3%
ROCE	-33.1%	-119.4%	-71.2%	-104.7%		
ROCE ROE	-33.1% -952.1%	-119.4% 284.0%	-71.2% 95.7%	96.6%	37.9%	17.7%
						17.7% 18.1%
ROE	-952.1%	284.0%	95.7%	96.6%	37.9%	18.1%
ROE Adjusted FCF yield	-952.1% -45.7%	284.0% -59.0%	95.7% -2.0%	96.6% 1.7%	37.9% 14.3%	
ROE Adjusted FCF yield Dividend yield	-952.1% -45.7% 0.0%	284.0% -59.0% 0.0%	95.7% -2.0% 0.0%	96.6% 1.7% 0.0%	37.9% 14.3% 0.0%	18.1% 0.0% 0.0
ROE Adjusted FCF yield Dividend yield DPS	-952.1% -45.7% 0.0% 0.0	284.0% -59.0% 0.0% 0.0	95.7% -2.0% 0.0% 0.0	96.6% 1.7% 0.0% 0.0	37.9% 14.3% 0.0% 0.0	18.1% 0.0% 0.0 -0.59
ROE Adjusted FCF yield Dividend yield DPS EPS reported	-952.1% -45.7% 0.0% 0.0 -460.78	284.0% -59.0% 0.0% 0.0 -173.62	95.7% -2.0% 0.0% 0.0 -1.33	96.6% 1.7% 0.0% 0.0 -2.68	37.9% 14.3% 0.0% 0.0 -1.10	18.1% 0.0% 0.0 -0.59
ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV	-952.1% -45.7% 0.0% 0.0 -460.78	284.0% -59.0% 0.0% 0.0 -173.62	95.7% -2.0% 0.0% 0.0 -1.33	96.6% 1.7% 0.0% 0.0 -2.68	37.9% 14.3% 0.0% 0.0 -1.10	18.1% 0.0% 0.0 -0.59 17.6
ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios	-952.1% -45.7% 0.0% 0.0 -460.78 0.2	284.0% -59.0% 0.0% 0.0 -173.62 0.3	95.7% -2.0% 0.0% 0.0 -1.33 30.0	96.6% 1.7% 0.0% 0.0 -2.68 14.1	37.9% 14.3% 0.0% 0.0 -1.10 17.6	18.1% 0.0% 0.0 -0.59 17.6
ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales EV/EBITDA	-952.1% -45.7% 0.0% 0.0 -460.78 0.2 0.3 -0.0 11.6	284.0% -59.0% 0.0% 0.0 -173.62 0.3 -0.6 0.1 -0.8	95.7% -2.0% 0.0% 0.0 -1.33 30.0 -2.0 0.4 -12.3	96.6% 1.7% 0.0% 0.0 -2.68 14.1 -1.0 0.3 -6.4	37.9% 14.3% 0.0% 0.0 -1.10 17.6 -1.0 0.3 116.9	18.1% 0.0% 0.0 -0.59 17.6 -0.8 0.3 12.7
ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales	-952.1% -45.7% 0.0% 0.0 -460.78 0.2	284.0% -59.0% 0.0% 0.0 -173.62 0.3 -0.6 0.1	95.7% -2.0% 0.0% 0.0 -1.33 30.0	96.6% 1.7% 0.0% 0.0 -2.68 14.1	37.9% 14.3% 0.0% 0.0 -1.10 17.6	18.1% 0.0% 0.0 -0.59 17.6 -0.8 0.3

Update - 15.02.2024



### **Disclosures**

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

#### Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
Marley Spoon Group SE	2

Historical target price and ratir	ng changes for Marley Spoon	Group SE			
Company	Date	Analyst	Rating	Target Price	Close
Marley Spoon Group SE	31.01.2024	Schüssler, Mark	Buy	EUR 8.60	EUR 2.20
	14.11.2023	Schüssler, Mark	Buy	EUR 8.20	EUR 4.34

Update - 15.02.2024



#### 1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

### 2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

### 3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

### 4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

#### 5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

#### 6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

### 7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

### 8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 15/02/2024 07:56 AM

Date of publication dissemination: 15/02/2024 07:57 AM

Update - 15.02.2024



### **Contacts**

### **NuWays AG**

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



**Philipp Sennewald** 

Analyst

philipp.sennewald@nuways-ag.com



**Henry Wendisch** 

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/>



<u>Linkedl</u>

